Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
Authors
Keywords
-
Journal
LEUKEMIA
Volume 32, Issue 1, Pages 102-110
Publisher
Springer Nature
Online
2017-06-06
DOI
10.1038/leu.2017.179
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
- (2016) S. V. Rajkumar et al. BLOOD
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics
- (2016) Najoua Lalaoui et al. CANCER CELL
- Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study
- (2016) Tasnim Chagtai et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis
- (2015) Lucas K Smith et al. NATURE MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
- (2015) Brian A. Walker et al. Nature Communications
- Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB
- (2015) Yulia N. Demchenko et al. Oncotarget
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- (2014) J. R. Sawyer et al. BLOOD
- Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
- (2014) Laura Tornatore et al. CANCER CELL
- A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
- (2014) Eileen M. Boyle et al. GENES CHROMOSOMES & CANCER
- An overview of the progress in the treatment of multiple myeloma
- (2014) Robert A Kyle et al. Expert Review of Hematology
- Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
- (2013) G. J. Morgan et al. CLINICAL CANCER RESEARCH
- Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma
- (2013) S. Van Wier et al. HAEMATOLOGICA
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR
- (2013) M F Kaiser et al. LEUKEMIA
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- IMWG consensus on risk stratification in multiple myeloma
- (2013) W J Chng et al. LEUKEMIA
- NF- B, the first quarter-century: remarkable progress and outstanding questions
- (2012) M. S. Hayden et al. GENES & DEVELOPMENT
- A20 and CYLD Do Not Share Significant Overlapping Functions during B Cell Development and Activation
- (2012) Yuanyuan Chu et al. JOURNAL OF IMMUNOLOGY
- The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy
- (2011) Kevin D. Boyd et al. GENES CHROMOSOMES & CANCER
- Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
- (2011) Gareth J Morgan et al. LANCET ONCOLOGY
- A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
- (2011) K D Boyd et al. LEUKEMIA
- A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
- (2010) B. A. Walker et al. BLOOD
- Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome
- (2010) N. J. Dickens et al. CLINICAL CANCER RESEARCH
- Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia
- (2010) C. J. Schwab et al. GENES CHROMOSOMES & CANCER
- The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance
- (2010) F. M. Ross et al. HAEMATOLOGICA
- Prognostic Significance of Copy-Number Alterations in Multiple Myeloma
- (2009) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started